JP2014510064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510064A5 JP2014510064A5 JP2013555631A JP2013555631A JP2014510064A5 JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5 JP 2013555631 A JP2013555631 A JP 2013555631A JP 2013555631 A JP2013555631 A JP 2013555631A JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- formula
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 230000001780 adrenocortical effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446716P | 2011-02-25 | 2011-02-25 | |
| US61/446,716 | 2011-02-25 | ||
| US201161500272P | 2011-06-23 | 2011-06-23 | |
| US61/500,272 | 2011-06-23 | ||
| PCT/US2012/026744 WO2012116362A2 (en) | 2011-02-25 | 2012-02-27 | Chalcone derivatives as nrf2 activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510064A JP2014510064A (ja) | 2014-04-24 |
| JP2014510064A5 true JP2014510064A5 (enExample) | 2015-04-16 |
Family
ID=46721498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555631A Pending JP2014510064A (ja) | 2011-02-25 | 2012-02-27 | Nrf2活性剤としてのカルコン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140088052A1 (enExample) |
| EP (1) | EP2678305A4 (enExample) |
| JP (1) | JP2014510064A (enExample) |
| AU (1) | AU2012222074A1 (enExample) |
| CA (1) | CA2827990A1 (enExample) |
| WO (1) | WO2012116362A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012174436A1 (en) | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2015187934A1 (en) * | 2014-06-06 | 2015-12-10 | Cureveda, Llc | Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use |
| ES2570452B1 (es) * | 2014-10-15 | 2017-04-19 | Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa | Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| WO2016153432A1 (en) * | 2015-03-23 | 2016-09-29 | Nanyang Polytechnic | Drugs from substituted phenyl cinnamyl ketones |
| CA3059192A1 (en) * | 2016-05-26 | 2017-11-30 | The Regents Of The University Of California | Compounds and methods for hematopoietic regeneration |
| UY37551A (es) | 2016-12-27 | 2018-07-31 | Biogen Ma Inc | Activador de nrf2 |
| CN107056707B (zh) * | 2017-01-23 | 2019-08-23 | 温州医科大学 | 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用 |
| WO2020041169A2 (en) | 2018-08-20 | 2020-02-27 | Janssen Pharmaceutica Nv | Inhibitors of keap1-nrf2 protein-protein interaction |
| WO2020094767A1 (en) * | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| CN111792990A (zh) * | 2019-04-09 | 2020-10-20 | 中国科学院上海药物研究所 | 一种不饱和酮类化合物、其制备方法和用途 |
| JP2023518027A (ja) * | 2020-03-13 | 2023-04-27 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Gpx4化合物及び組成物、並びにそれを使用する治療方法 |
| CN116916917A (zh) * | 2021-01-07 | 2023-10-20 | 菲利普莫里斯生产公司 | 包含新烟草碱的组合物及其用途 |
| US20240335395A1 (en) * | 2021-07-15 | 2024-10-10 | Allspim | Compositions and methods for preventing and/or treating disease associated with il-23 expression |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| CN115572255A (zh) * | 2022-04-29 | 2023-01-06 | 无锡捷化医药科技有限公司 | 一种查尔酮类化合物的制备方法 |
| CN115433073B (zh) * | 2022-08-15 | 2024-04-19 | 兰州大学 | 一种卡瓦胡椒素b类似物的制备方法及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0740105B2 (ja) * | 1986-03-14 | 1995-05-01 | 清蔵 宮田 | 非線形光学素子 |
| JPH02178249A (ja) * | 1988-12-28 | 1990-07-11 | Mitsubishi Kasei Corp | 光学活性ケトンの製造法 |
| US20030065039A1 (en) * | 1997-06-26 | 2003-04-03 | Statens Serum Institute | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
| DE69814428T2 (de) * | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
| WO2000018390A1 (fr) * | 1998-09-28 | 2000-04-06 | Hsp Research Institute, Inc. | Inducteurs d'expression de proteine de choc thermique |
| WO2003033662A2 (en) * | 2001-10-16 | 2003-04-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| KR100830541B1 (ko) * | 2006-08-11 | 2008-05-21 | 충남대학교산학협력단 | 인터루킨-5 저해효과를 갖는 신규 찰콘계 유도체 |
-
2012
- 2012-02-27 CA CA2827990A patent/CA2827990A1/en not_active Abandoned
- 2012-02-27 EP EP12750204.5A patent/EP2678305A4/en not_active Withdrawn
- 2012-02-27 US US14/000,816 patent/US20140088052A1/en not_active Abandoned
- 2012-02-27 JP JP2013555631A patent/JP2014510064A/ja active Pending
- 2012-02-27 AU AU2012222074A patent/AU2012222074A1/en not_active Abandoned
- 2012-02-27 WO PCT/US2012/026744 patent/WO2012116362A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510064A5 (enExample) | ||
| JP2004514739A5 (enExample) | ||
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| JP2016510012A5 (enExample) | ||
| JP2018199684A5 (enExample) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| AR098982A1 (es) | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol | |
| Scichilone et al. | Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD | |
| JP6501774B2 (ja) | Maba化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2013542940A5 (enExample) | ||
| JP2010132695A5 (enExample) | ||
| SI2393477T1 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| JP2015519356A5 (enExample) | ||
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| US10258634B2 (en) | Ciclesonide for the treatment of airway disease in horses | |
| JP2016510012A (ja) | Maba化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2020023536A (ja) | Copdの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| JP2016516762A5 (enExample) | ||
| RU2015145135A (ru) | Лечение воспалительных расстройств | |
| JP2014520874A5 (enExample) | ||
| JP2011500731A5 (enExample) | ||
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| JP2007518817A5 (enExample) | ||
| JP2017513866A5 (enExample) | ||
| JP2019519572A5 (enExample) |